삼성서울병원

Ko En

Hematology-Oncology Kim, Seung Tae M.D

Expertise
Gastric Cancer and Colorectal cancer
Treament Schedule 05 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM
Treament Schedule 06 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
SAT
29
SUN
30
AM
PM

Medical Education

Dongguk University College of Medicine

Post-Graduate Training

Fellowship   Samsung Medical Center
Korea University Anam Hospital
Residency   Samsung Medical Center
Internship   Samsung Medical Center

Professional Memberships

Personalized Medicine

Selected Publications

  • EUR RADIOL 2021 10.1007/s00330-021-08094-3 Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer Cha1, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D
    View PubMed
  • NATURE 2021 10.1038/s41586-021-03515-1 ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Yen1, I; Shanahan, F; Lee, J; Hong, YS; Shin, SJ; Moore, AR; Sudhamsu, J; Chang, MT; Bae, I; Dela Cruz, D; Hunsaker, T; Klijn, C; Liau, NPD; Lin, E; Martin, SE; Modrusan, Z; Piskol, R; Segal, E; Venkatanarayan, A; Ye, X; Yin, JP; Zhang, LX; Kim, JS; Lim, HS; Kim, KP; Kim, YJ; Han, HS; Lee, SJ; Kim, ST; Jung, M; Hong, YH; Noh, YS; Choi, M; Han, O; Nowicka, M; Srinivasan, S; Yan, YB; Kim, TW; Malek, S
    View PubMed
  • CANCER RES TREAT 2021 10.4143/crt.2020.1233 Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion Yoo1, C; Oh, CR; Kim, ST; Bae, WK; Choi, HJ; Oh, D; Lee, MA; Ryoo, BY
    View PubMed
  • INVEST NEW DRUG 2021 10.1007/s10637-021-01110-9 A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer Jeong1, H; Hong, YS; Kim, JE; Lim, HS; Ahn, JB; Shin, SJ; Park, YS; Kim, ST; Han, SW; Kim, TY; Kim, TW
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed